RedHill Biopharma
TEL AVIV, L3 · Biotechnology, Healthcare, Health Care · 135 employees
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious, and oncological diseases in the U.S. The company markets Talicia®, an FDA-approved treatment for H. pylori infection, and is advancing late-stage programs including opaganib, a first-in-class SPHK2 inhibitor; RHB-204 for Crohn’s diseas
Funding history
- Post-IPO Equity — $6.0M — Jun 2026
- Corporate Round — $4.0M — Oct 2025
- Venture - Series Unknown — $10.0M — Feb 2024
- Seed — $4.0M — Oct 2023
- Seed — $2.7M — Aug 2023
Recent signals
- Jun 18, 2026: Raised $6.0M in Post-IPO Equity
- Oct 20, 2025: Raised $4.0M in Corporate Round
- Oct 01, 2024: RedHill Renews Contract with Medi-Cal to Maintain Talicia® Reimbursement Without Prior Authorization
- Feb 05, 2024: Raised $10.0M in Venture - Series Unknown
- Oct 12, 2023: Raised $4.0M in Seed
- Aug 07, 2023: Raised $2.7M in Seed
- Nov 22, 2021: Raised $5.0M in Venture - Series Unknown
- Nov 08, 2021: Raised funding in Corporate Round
See plans & pricing → Track RedHill Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.